TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alx Oncology Holdings Inc.
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 trials.

Insights
ALXO   positive

The company is advancing multiple clinical-stage candidates with demonstrated potential in oncology. Evorpacept has shown positive results in combination trials (92% complete response rate in iNHL), and the company's participation in a major healthcare conference indicates investor confidence and continued pipeline progress.